Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

Simon Fraser University

$36,000.00

Radiometals: Novel methods in production, radiochemistry and application

FY 2016-17

Summary
Radioisotopes can be produced either in nuclear reactors or particle accelerators, with the former having long-defined the global production paradigm due to the higher power of reactors and relative scarcity of compact, commercially available accelerators (cyclotrons). However, the global landscape is changing; cyclotron-based isotope production is now more prevalent, while reactors around the world are scheduled to go off-line within the next few years. This perceived threat to our isotope supply is re-defining how and where the isotopes most vital for use in science and medicine are made. Canada has long recognized this issue and has invested heavily in cyclotron technology. This country now boasts one of the most advanced particle accelerator infrastructures in the world, and with it, a strong radiopharmaceutical community. This proposal will develop technology and chemistry that will enable the Canadian and international radiopharmaceutical research communities to drive innovation by enabling the development of popular, but difficult to produce and expensive metallic radioisotopes; isotopes that require high-power infrastructure to generate usable quantities. To do so, this proposal will leverage TRIUMF's 500 MeV cyclotron to irradiate thorium and uranium targets to produce two radiometals, 225Ra and 224Ra, as parent isotopes for a series of daughters, namely 225Ac, 212,213Bi and 212Pb. These isotopes have noted applications as therapeutic beta, alpha, conversion electron and Auger emitters. The short path length and high linear energy transfer (LET) of the emitted particles are very effective in killing cells and cancerous tissues. Such applications have been recognized since the time of Marie Curie, but frustratingly, more than a century later, research continues to be limited by the poor availability of many promising isotopes. Initial studies will use TRIUMF's Isotope Separation Online (ISOL) facility to implant Ra isotopes, with later studies set to isolate and study their coordination chemistry. The proposed research effort will be an integral part of a larger training program between TRIUMF and SFU, helping to establish a new generation of scientists in accelerator-based isotope production and radiochemistry using therapeutic radionuclei. Trainees will isolate and purify sufficient quantities of all isotopes for chemistry studies, which will lay the groundwork for future incorporation into proteins, peptides, and oligonucleotides, etc. as possible therapeutic agents. This work will include training in target preparation, irradiated target manipulation, dissolution, radionuclide purification and radiochemistry studies. All trainees are subjected to a multi-disciplinary research environment, resulting in highly qualified individuals with a versatile skill set that bridges the fields of physics, chemistry and biology.
Program
Discovery Grants Program - Individual
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2016-04413
Name nom
Schaffer, Paul
Department département
Chemistry - Chemistry
Organization id
5
Institution établissement
Simon Fraser University
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
36000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1504
Committee name en
Chemistry
Committee name fr
Chimie
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
2402
Research subject group en
Nuclear engineering
Research subject group fr
Génie nucléaire
Research subject en
Radioactive materials
Research subject fr
Matériaux radioactifs
Partie
1
Nb partie
5
Application title
Radiometals: Novel methods in production, radiochemistry and application
Keyword
NSERC
Application summary
Radioisotopes can be produced either in nuclear reactors or particle accelerators, with the former having long-defined the global production paradigm due to the higher power of reactors and relative scarcity of compact, commercially available accelerators (cyclotrons). However, the global landscape is changing; cyclotron-based isotope production is now more prevalent, while reactors around the world are scheduled to go off-line within the next few years. This perceived threat to our isotope supply is re-defining how and where the isotopes most vital for use in science and medicine are made. Canada has long recognized this issue and has invested heavily in cyclotron technology. This country now boasts one of the most advanced particle accelerator infrastructures in the world, and with it, a strong radiopharmaceutical community. This proposal will develop technology and chemistry that will enable the Canadian and international radiopharmaceutical research communities to drive innovation by enabling the development of popular, but difficult to produce and expensive metallic radioisotopes; isotopes that require high-power infrastructure to generate usable quantities. To do so, this proposal will leverage TRIUMF's 500 MeV cyclotron to irradiate thorium and uranium targets to produce two radiometals, 225Ra and 224Ra, as parent isotopes for a series of daughters, namely 225Ac, 212,213Bi and 212Pb. These isotopes have noted applications as therapeutic beta, alpha, conversion electron and Auger emitters. The short path length and high linear energy transfer (LET) of the emitted particles are very effective in killing cells and cancerous tissues. Such applications have been recognized since the time of Marie Curie, but frustratingly, more than a century later, research continues to be limited by the poor availability of many promising isotopes. Initial studies will use TRIUMF's Isotope Separation Online (ISOL) facility to implant Ra isotopes, with later studies set to isolate and study their coordination chemistry. The proposed research effort will be an integral part of a larger training program between TRIUMF and SFU, helping to establish a new generation of scientists in accelerator-based isotope production and radiochemistry using therapeutic radionuclei. Trainees will isolate and purify sufficient quantities of all isotopes for chemistry studies, which will lay the groundwork for future incorporation into proteins, peptides, and oligonucleotides, etc. as possible therapeutic agents. This work will include training in target preparation, irradiated target manipulation, dissolution, radionuclide purification and radiochemistry studies. All trainees are subjected to a multi-disciplinary research environment, resulting in highly qualified individuals with a versatile skill set that bridges the fields of physics, chemistry and biology.